Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Fineline Cube Sep 10, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Deals

Sun Yat-sen University and KingMed Diagnostics Collaborate on Talent Development and Research

Fineline Cube Jun 25, 2024

On June 20, 2024, the School of Public Health (Shenzhen) of Sun Yat-sen University and...

Company Deals

AnDiConBio Secures Over RMB 200 Million in Series A Financing to Advance Respiratory and Pain Therapies

Fineline Cube Jun 25, 2024

AnDiConBio, a Zhejiang-based innovative pharmaceutical company specializing in respiratory infections and pain management, has reportedly...

Company Drug

Haisco Pharmaceutical Gets NMPA Green Light for Cofrogliptin to Treat Type 2 Diabetes

Fineline Cube Jun 25, 2024

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received marketing approval...

Company Drug

Gan & Lee Pharmaceuticals’ GZR18 Outperforms Market Similars in Weight Reduction Study

Fineline Cube Jun 25, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the presentation of...

Company Drug

Novo Nordisk’s Once-Weekly Insulin Awiqli Approved by China’s NMPA for Type 2 Diabetes

Fineline Cube Jun 25, 2024

The National Medical Products Administration (NMPA) has granted market approval for Awiqli (insulin icodec), a...

Company Drug

Innovent Biologics’ Mazdutide Shows Promise in Phase III Obesity Trial

Fineline Cube Jun 25, 2024

Innovent Biologics Inc. (HKG: 1801), a biopharmaceutical company based in China, has announced the presentation...

Company Drug

Takeda’s Fruquintinib for Metastatic Colorectal Cancer Receives European Commission Marketing Approval

Fineline Cube Jun 24, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its partner Takeda (TYO: 4502,...

Company Deals

ClouDr Secures Exclusive Sub-Licensing Rights for Iloprost Infusion Solution

Fineline Cube Jun 24, 2024

Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), operating under the brand name “ClouDr,”...

Legal / IP

Biocytogen Secures US Patent for RenLite Fully Human Common Light Chain Mouse Platform

Fineline Cube Jun 24, 2024

Biocytogen (HKG: 2315), a biopharmaceutical company based in China, has announced that it has been...

Company Drug

ImmuneOnco Biopharmaceuticals Receives NMPA Approval for CD47 and CD20 Dual-Targeted BsAb in SLE

Fineline Cube Jun 24, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received clinical trial...

Company Deals

Shanghai Pharmaceuticals’ Subsidiary Shaphar Med Collaborates with Magic Med to Enter Oncology

Fineline Cube Jun 24, 2024

Shanghai Pharmaceuticals Holding Co., Ltd (SPH, SHA: 601607; HKG: 2607), a leading pharmaceutical company in...

Company Drug

Sichuan Biokin Pharmaceutical Gets NMPA Go-Ahead for BL-M17D1 Solid Tumor Clinical Study

Fineline Cube Jun 24, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced...

Company Drug

StarryGene Initiates Phase I Clinical Trial for XMVA09 Gene Therapy in wAMD

Fineline Cube Jun 24, 2024

StarryGene, a biotech company specializing in gene therapy and based in Hefei, China, has announced...

Company Drug

Gilead’s Lenacapavir Shows 100% Efficacy in Phase III HIV PrEP Study

Fineline Cube Jun 24, 2024

Gilead Sciences Inc. (NASDAQ: GILD), a U.S. biopharmaceutical company, has announced topline results from the...

Policy / Regulatory

Hefei Airport Port Designated as Drug Import Port by Chinese Authorities

Fineline Cube Jun 24, 2024

Hefei Airport Port, located in the city of Hefei, China, has been designated as a...

Company Drug

Zai Lab’s Partner Argenx Receives FDA Approval for CIDP Treatment Vygart Hytrulo

Fineline Cube Jun 24, 2024

Argenx SE (NASDAQ: ARGX), the U.S. partner of China-based biopharmaceutical company Zai Lab Ltd (NASDAQ:...

Company Deals

Inkon Life Technology Partners with United Imaging to Establish Advanced Medical Centers and Digital Platform

Fineline Cube Jun 24, 2024

Inkon Life Technology Co., Ltd. (SHE: 300143), a Shenzhen-based service provider specializing in stereotactic radiotherapy...

Company Deals

METiS Therapeutics Secures USD 100 Million in Series C Financing to Advance AI Drug Delivery

Fineline Cube Jun 24, 2024

METiS Therapeutics, a biopharmaceutical company based in Cambridge, Massachusetts, has secured USD 100 million in...

Company Drug

Qilu Pharmaceutical’s Generic Version of Vyndaqel Receives NMPA Marketing Approval

Fineline Cube Jun 21, 2024

The National Medical Products Administration (NMPA) has granted marketing approval to Qilu Pharmaceutical’s generic version...

Company Deals Medical Device

Jiangsu Yuyue Medical Teams Up with China Unicom for Digital Healthcare Innovation

Fineline Cube Jun 21, 2024

Shanghai-based Jiangsu Yuyue Medical Equipment Inc. (SHE: 002223) has announced a strategic partnership with China...

Posts pagination

1 … 394 395 396 … 718

Recent updates

  • Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers
  • METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform
  • Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection
  • CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours
  • HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Company Drug

CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.